Abbott launches rapid point-of-care HbA1c test to diagnose diabetes
Abbott is debuting its Afinion HbA1c Dx assay for use on the Afinion 2 Analyzer, as well as the Afinion AS100 Analyzer.
The Afinion HbA1c Dx assay is the first and only rapid point-of-care test cleared by the Food and Drug Administration to aid healthcare professionals in the diagnosis of diabetes and the assessment of patients' risk of developing the condition, the company said.
The Afinion HbA1c Dx meets FDA's stringent requirements for performance testing for diagnostic use claims. The test delivers accurate and precise glycated hemoglobin (HbA1c) results in only three minutes, enabling clinicians to diagnose patients and help them formulate individualized care plans during a single doctor's office visit, the company said.
The Afinion HbA1c Dx assay (approved for monitoring and diagnosis) complements the Afinion HbA1c assay (approved for monitoring only), the number one point-of-care HbA1c test in the United States for monitoring long-term glycemic control in diabetes.
“As diagnostics continue to move to point-of-care settings such as physician office labs, the Afinion HbA1c Dx rapid assay shows how Abbott is once again setting new standards for innovation in the diagnosis and monitoring of diabetes," said Elizabeth Balthrop, Abbott divisional vice president, cardiometabolic and informatics, rapid diagnostics. "In addition to giving physicians the certainty of diagnosis they need to make informed decisions during a patient visit, the HbA1c Dx assay gives people living with diabetes near real-time results, so that in consultation with their doctor they can make adjustments to their lifestyle and better manage their condition."
"Rapid, reliable diabetes screening at the point of care enables healthcare providers to immediately link patients to comprehensive care that can help prevent the serious consequences of the disease," said Richard Kahn, former chief scientific and medical officer of the American Diabetes Association. "In addition, point-of-care diagnosis can enhance clinical efficiencies for busy practices and, at a population level, help stem the massive economic and societal impacts of diabetes in the U.S."
The Afinion HbA1c Dx assay is the first and only rapid point-of-care test cleared by the Food and Drug Administration to aid healthcare professionals in the diagnosis of diabetes and the assessment of patients' risk of developing the condition, the company said.
The Afinion HbA1c Dx meets FDA's stringent requirements for performance testing for diagnostic use claims. The test delivers accurate and precise glycated hemoglobin (HbA1c) results in only three minutes, enabling clinicians to diagnose patients and help them formulate individualized care plans during a single doctor's office visit, the company said.
The Afinion HbA1c Dx assay (approved for monitoring and diagnosis) complements the Afinion HbA1c assay (approved for monitoring only), the number one point-of-care HbA1c test in the United States for monitoring long-term glycemic control in diabetes.
“As diagnostics continue to move to point-of-care settings such as physician office labs, the Afinion HbA1c Dx rapid assay shows how Abbott is once again setting new standards for innovation in the diagnosis and monitoring of diabetes," said Elizabeth Balthrop, Abbott divisional vice president, cardiometabolic and informatics, rapid diagnostics. "In addition to giving physicians the certainty of diagnosis they need to make informed decisions during a patient visit, the HbA1c Dx assay gives people living with diabetes near real-time results, so that in consultation with their doctor they can make adjustments to their lifestyle and better manage their condition."
"Rapid, reliable diabetes screening at the point of care enables healthcare providers to immediately link patients to comprehensive care that can help prevent the serious consequences of the disease," said Richard Kahn, former chief scientific and medical officer of the American Diabetes Association. "In addition, point-of-care diagnosis can enhance clinical efficiencies for busy practices and, at a population level, help stem the massive economic and societal impacts of diabetes in the U.S."